It is evident that the downregulation of RIP1, RIP3 and MLKL is associated with the inhibition of cancer cell growth and increased sensitivity to RT in breast cancer; in addition, necrosulfonamide (NSA), an inhibitor of necroptosis, leads to significant tumor growth suppression [74]. Here, RIPK3 is linked to breast carcinoma.